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Abstract
Background: In chronic liver disease, hepatic stellate cells (HSC) transdifferentiate into myofibroblasts, promoting
extracellular matrix (ECM) synthesis and deposition. Stimulation of HSC by transforming growth factor-b (TGF-b) is a crucial
event in liver fibrogenesis due to its impact on myofibroblastic transition and ECM induction. In contrast, hepatocyte growth
factor (HGF), exerts antifibrotic activities. Recently, miR-29 has been reported to be involved in ECM synthesis. We therefore
studied the influence of HGF and TGF-b on the miR-29 collagen axis in HSC.
Methodology: HSC, isolated from rats, were characterized for HGF and Met receptor expression by Real-Time PCR and
Western blotting during culture induced myofibroblastic transition. Then, the levels of TGF-b, HGF, collagen-I and -IV mRNA,
in addition to miR-29a and miR-29b were determined after HGF and TGF-b stimulation of HSC or after experimental fibrosis
induced by bile-duct obstruction in rats. The interaction of miR-29 with 39-untranslated mRNA regions (UTR) was analyzed
by reporter assays. The repressive effect of miR-29 on collagen synthesis was studied in HSC treated with miR-29-mimicks by
Real-Time PCR and immunoblotting.
Principal Findings: The 39-UTR of the collagen-1 and 24 subtypes were identified to bind miR-29. Hence, miR-29a/b
overexpression in HSC resulted in a marked reduction of collagen-I and -IV synthesis. Conversely, a decrease in miR-29 levels
is observed during collagen accumulation upon experimental fibrosis, in vivo, and after TGF-b stimulation of HSC, in vitro.
Finally, we show that during myofibroblastic transition and TGF-b exposure the HGF-receptor, Met, is upregulated in HSC.
Thus, whereas TGF-b stimulation leads to a reduction in miR-29 expression and de-repression of collagen synthesis,
stimulation with HGF was definitely associated with highly elevated miR-29 levels and markedly repressed collagen-I and -IV
synthesis.
Conclusions: Upregulation of miRNA-29 by HGF and downregulation by TGF-b take part in the anti- or profibrogenic
response of HSC, respectively.
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Introduction
Progressive liver fibrosis due to chronic viral hepatitis,
autoimmune, metabolic or hereditary disorders is a leading cause
of morbidity and mortality in the Western world (reviewed in
[1,2,3]). Regardless of the underlying etiology, liver fibrosis is
characterized by an excessive deposition and reorganization of
extracellular matrix (ECM) with a dramatic increase in non-
collagenous and collagenous ECM proteins. The fibrillar collagen
type I, is encoded by two different genes, col1A1 and col1A2, and
accounts for 36% of the total collagens in ECM of healthy liver.
During liver fibrogenesis, collagen type I is the predominant
isoform deposited into the perisinusoidal space. However, collagen
type IV, that constitutes less than 10% of total collagen in the
normal liver, is most dramatically upregulated in fibrosis [4,5,6].
In the fibrotic liver, hepatic stellate cells (HSC) undergo
myofibroblastic transdifferentiation. These myofibroblastic HSC
are regarded as the main source of ECM production [1,3,7,8]
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cytes may also participate in the synthesis and restructuring of the
connective tissue [9,10]. HSC get activated in response to chronic
liver injury by proinflammatory and profibrogenic mediators such
as transforming growth factor-b (TGF-b) [11,12] and platelet-
derived growth factor b [13,14]. TGF-b is recognized as the main
profibrogenic mediator, triggering the myofibroblastic transition of
HSC. Furthermore, it promotes the synthesis of ECM proteins,
and inhibits expression and activity of matrix degrading enzymes
in HSC [15].
TGF-b stimulated matrix production and deposition has been
shown in a wide range of models of experimental fibrosis [16,17]
and in patients with chronic hepatitis and cirrhosis [18,19,20].
Interestingly, there is good evidence for hepatic growth factor
(HGF) opposing TGF-b signalling by reducing TGF-b mRNA
levels [21]. HGF is a multifunctional cytokine that elicits
mitogenic, motogenic, and morphogenic properties [22,23] by
activation of the tyrosine kinase receptor Met, a product of the
proto-oncogene c-met [24,25]. In addition, HGF is known to
inhibit accumulation of extracellular matrix and development of
hepatic fibrosis in vivo [26,27,28]. TGF-b c a ni nt u r nd r a m a t -
ically suppress HGF mRNA expression in HSC, demonstrating
the reciprocal effects of these cytokines on ECM accumulation
[29].
The synthesis of extracellular matrix proteins is modulated by
microRNA-29 (miR-29) in extrahepatic tissue [30,31,32,33].
Recent reports suggest that miR-29 is also involved in the
synthesis of collagen type I in liver fibrosis [34,35]. The miR-29
family consists of miR-29a, miR-29b (b1,b 2), and miR-29c,
which differ in only two or three nucleotides, respectively. The
genes for miR-29a and miR-29b1 are both located on
chromosome 7, whereas the genes for miR-29c and miR-29b2
are located on chromosome 1. Each gene pair is transcribed in
tandem resulting in a common pri-miRNA from which the
mature miR-29 members are released after further processing
[36,37].
In the present study, we investigate the role of the members of
the miR-29 family in HGF mediated repression of collagen
synthesis. We demonstrate that miR-29 is not only involved in
collagen type I but also in type IV synthesis of myofibroblastic
HSC. The importance of miR-29 in hepatic collagen homeostasis
is underlined by our in vivo data that shows the lack of miR-29 in
severe experimental fibrosis after bile duct obstruction. This loss of
miR-29 is suggested to be due to the response of HSC to exposure
to profibrogenic mediators as shown by our in vitro findings on
TGF-b stimulated HSC. Whereas TGF-b stimulation leads to
decreased miR-29 levels, but to pronounced upregulation of
collagen synthesis, HGF stimulation leads to elevated miR-29
expression, but to repression of collagen synthesis. Thus, our data
provide detailed evidence for the antifibrotic action of miR-29 in
response to HGF signalling that is counteracted by the profibrotic
growth factor TGF-b.
Materials and Methods
Isolation of primary HSC from rat, cell culture and
stimulation of HSC
Isolation and plastic-induced myofibroblastic in vitro activation
of primary HSC was performed as previously described [38,39].
Cells were maintained in Dulbecco’s modified Eagles medium
(DMEM) with 10% fetal calf serum (FCS) at 37uC and 5% CO2 in
a humidified atmosphere. HSC at day 3 are considered as
quiescent relative to day 7 of HSC culture, when they express all
features of myofibroblasts and considered as myofibroblastic cells.
For miR-29 transfection assays, HSC-T6 cells (kindly provided by
SL Friedman) were cultured in agreement to the previous
description [40,41]. In order to stimulate HSC with TGF-b cells
were cultured to 90% confluency in DMEM containing 10% FCS
and starved out for 24 h in DMEM containing 0.5% FCS. For
HGF stimulation HSC-T6 cells were cultured to a confluency of
70% in DMEM containing 10% FCS. After 24 h 10 ng/ml TGF-
b1 (R&D Systems, Wiesbaden-Nordenstadt, Germany), or 40 ng/
ml recombinant hHGF (Dianova, Hamburg, Germany) was added
and cells were cultured for a further 24 h.
Bioinformatics
In order to search miRNA targets, the databases miRanda
(http://www.microrna.org) [42,43], Targetscan (http://www.
targetscan.org) [44], and Pictar (http://pictar. bio.nyu.edu) [45]
were queried.
Plasmid constructs
The 39-UTR of collagen 4A1 (col4A1) and collagen 4A5
(col4A5) transcripts bearing putative miRNA-binding sites for
miR-29 were amplified from genomic rat DNA using the primer
shown in the Table S1. Furthermore, the putative binding sites of
collagen 1A1 (col1A1), collagen 1A2 (col1A2), collagen 4A1(co-
l4A1), and collagen 4A5 (col4A5) as well as the corresponding
mutants containing two point mutations were cloned by insertion
of the dimerized oligonucleotides shown in the Table S2.
Amplicons and oligonucleotide dimers were cloned downstream
of the renilla luciferase reporter of the psiCHECK
TM-2 vector
(Ambion, Austin, USA) (Figure 1 A).
miRNA transfection and reporter assays
miRNA mimicking miR-29a, miR-29b and a scrambled
miRNA control were obtained from Dharmacon (Lafayette,
USA). HSC were seeded in 6-well plates, incubated overnight to
a density of 90% and transfected using Lipofectamine 2000
(Invitrogen, Karlsruhe, Germany) as instructed. Afterwards, the
cells were lysed either in SDS-lysis buffer (15 mM Tris-HCL
pH 6.8, 0.5% SDS, 2.5% glycerol) containing protease inhibitors
(Roche Applied Science, Mannheim, Germany) or in Qiazol
(Qiagen, Hilden, Germany) and stored for subsequent protein or
RNA analyses, respectively.
For reporter assays, cells were seeded in 24-well plates to reach
90% confluency overnight. 50 nM miRNA and 2 mg/ml
psiCHECK
TM-2 reporter was used for transfection using Lipo-
fectamine 2000. The level of miR-29 transfected into HSC-T6
cells was analyzed by Real-Time PCR, demonstrating stable levels
between 8 h and 48 h post-transfection. Cells were therefore
harvested 24 hours after transfection and luciferase activity in the
samples was determined using the Dual Luciferase Reporter Assay
System (Promega, Mannheim, Germany) according to the
manufacturer’s recommendations. All samples were measured in
triplicate and experiments were each performed three times.
Total RNA extraction
Total RNA from snap-frozen cell culture and tissue samples was
isolated using the Qiazol reagent as instructed (Qiagen, Hilden,
Germany). Rat liver tissues were homogenized using the Precellys
24 tissue homogenizer (Peqlab Biotechnologie, Erlangen, Ger-
many) prior to extraction. Total RNA yields were determined by
A260 measurement using the ND-1000 NanoDrop spectropho-
tometer (NanoDrop, Wilmington, USA) and RNA integrity was
assessed by microcapillary electrophoresis (2100 BioAnalyser,
Agilent Technolologies, Waldbronn, Germany).
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microRNA was quantified by a two-step Real-Time PCR using
the miScript-Reverse Transcription Kit and the miRNA-SYBR
Green PCR Kit (Qiagen, Hilden, Germany). The first step
includes total RNA polyadenylation and reverse transcription,
followed by Real-Time PCR. Primers used for cDNA synthesis
and Real-Time PCR were selected and purchased from the
GeneGlobe Search Center (Qiagen). 2 ng of all samples were used
and processed in triplicate in agreement with the supplier’s
guidelines. Cellular miRNA levels were normalized using RNU6
as reference RNA.
Transcript quantification by Real-Time PCR
Total RNA concentrations were estimated by A260 measure-
ment. 1 mg of total RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems
Applera, Darmstadt, Germany) as instructed. 10 ng of cDNA were
used for Real-Time PCR using specific primers listed in Table S1
B and Power SYBR Green PCR Mastermix (Applied Biosystems
Applera). All reactions were performed in triplicate. Transcript
levels were evaluated by absolute quantification using an on-line
standard curve and corrected by normalization to the house-
keeping gene, hypoxanthine phosphoribosyltransferase (HPRT).
Immunoblotting
Total protein concentrations were determined using the BCA
protein assay (Thermo Scientific, Bonn, Germany). Equal amounts
of protein (10 mg) were resolved on 4–12% SDS-polyacrylamid gels
(Biorad, Mu ¨nchen, Germany), electrotransferred to Hybond ECL
nitrocellulose membranes (Amersham Biosciences, Mu ¨nchen,
Figure 1. Met and HGF expression in primary and immortalized HSC. Total RNA was extracted from primary rat HSC after the third, fifth and
seventh day of cell culture (3d, 5d, 7d) and from myofibroblastic HSC-T6 cells. Subsequently, c-met and HGF expression was determined (A–C). The c-
met and HGF transcript levels were quantified by Real-Time PCR and normalized using HPRT as house-keeping gene (A–C). The expression of c-met
increased during the differentiation process of primary HSC and achieved the highest level in the immortalized cell line HSC-T6 representing a
myofibroblastic phenotype [41], whereas HGF levels were shown to be opposite (A, B). Primary HSC at the 3rd culture day (prim. HSC) and
immortalized HSC (HSC-T6) were either untreated (2) or stimulated with TGF-b (+) and RNA levels of c-met and HGF were analyzed by Real-Time PCR
(C). The Met protein expression in HGF and TGF-b stimulated HSC-T6 (+HGF, +TGF-b) in comparison to untreated HSC-T6 cells (control) was shown by
Western blot analysis (D).
doi:10.1371/journal.pone.0024568.g001
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anti-collagenIV(1:5000)antibodies,bothfromAbcam(Cambridge,
UK), or with anti-Met antibodies (1:500) from Santa Cruz
(Heidelberg, Germany), or anti-actin antibodies (1:5000) from
Sigma-Aldrich (Hamburg, Germany). Signals were visualized and
quantified using enhanced chemiluminescence (ECL) substrate and
a FLUORCHEMHFC2 Alpha Ease scanner (Biozym, Hess.
Oldendorf, Germany).
Induction of biliary fibrosis by bile duct occlusion in rats
10 male Wistar rats (250–300 g) were housed in individual cages
with free access to regular chow and water. All experiments were
conducted in accordance with National Health and Medical
Research Committee Guidelines for Animal Experimentation and
approved by the local veterinary authority of North Rhine
Westphalia (reference number: K07,04/03). 5 animals were sham
operated and 5 animals were subjected to bile duct occlusion (BDO)
as described previously [46,47]. Livers were snap frozen in liquid
nitrogen and stored at minus 80uC for analysis of mRNA, protein
expression, and hydroxyproline content as described before [47].
Liver tissue from liver segment IV was fixed in 4% buffered
formaldehyde solution and embedded in paraffin for histopatholog-
ical evaluation after Gomori, HE and Elastica van Gieson staining.
Statistical analysis
Statistical analyses were performed using SPSS software 17
(Chicago, IL, USA). Data obtained from rat tissues was shown as
boxplots and subjected to analyses of variance (ANOVA) using
Dunnetts post-hoc comparison. Bar graphs show means 6 SEM
and values of p , 0.05 were considered statistically significant.
Results
HGF is known to suppress fibrosis [26,27,28] and its
antagonistic interaction with the TGF-b pathway leading to
collagen suppression has recently been shown in renal fibroblasts
[48,49]. Here, we studied the function of HGF in collagen
synthesis of primary HSC undergoing myofibroblastic activation
after primary culture for up to 7 days. Myofibroblastic transition of
primary HSC in culture resembles the process in vivo and is
characterized by the loss of vitamine A, increased proliferation,
and elevated expression of profibrogenic mediators and various
connective tissue proteins [5,11,29,39]. The most prominent
feature of the myofibroblastic transdifferentiation process, in vitro
and in vivo, is the enhanced expression of a-smooth muscle actin
(SMA). Therefore, we first demonstrated the process of myofibro-
blastic transdifferentiation by analysis of the induced SMA
expression of isolated rat HSC in culture (Figure S1).
The myofibroblastic transition of primary HSC was accompa-
nied by a reduction in HGF transcripts and a simultaneous increase
in the HGF receptor, c-met (Figure 1 A, B). The opposite effects in
HGF and c-met expression were most pronounced in HSC of the
HSC-T6 cell line, representing fully transdifferentiated myofibro-
blasticHSC[41].InHSC-T6HGFtranscriptswere lost whilethec-
met levels were high (Figure 1 A). Interestingly, TGF-b stimulation
of both, HSC at day 3 of primary culture and of myofibroblastic
HSC-T6 cells was capable of downregulating HGF and further
upregulating c-met (Figure 1 C). In line with the transcriptional
response, Met protein synthesis increased after TGF-b exposure in
HSC, but decreased after stimulation with HGF (Figure 1 D).
HGF generates antifibrotic effects in HSC by repression of
the collagen I and collagen IV synthesis and attenuating
the TGF-b expression
TGF-b is a highly potent profibrogenic growth factor that
activates and promotes collagen synthesis in HSC [4,12]. Whereas
stimulation of HSC with TGF-b induced the expression of various
collagen subunits such as col1A1, col1A2, col4A1, col4A5 in
addition to TGF-b, itself, the HGF transcript levels were markedly
repressed (Figure 2 A).
Figure 2. Contrary influence of TGF-b and HGF stimulation on collagen, but also on TGF-b and HGF expression, itself. Collagen 1A1
(col1A1), collagen 1A2 (col1A2), collagen 4A1 (col4A1), and collagen 4A5 (col4A5), HGF and TGF-b mRNA levels were compared by Real-Time PCR in
untreated (2) and in HSC-T6 cells stimulated either with TGF- b (+TGF- b) (A) or with HGF (+HGF) (B).
doi:10.1371/journal.pone.0024568.g002
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HGF lead to reduced expression of col1A1, col1A2, col4A1, and
col4A5, as well as TGF-b expression. However, there was no
remarkable change of HGF expression (Figure 2 B).
miR-29a and miR-29b regulate collagen I and IV synthesis
in activated HSC
Since miRNA has been shown to profoundly affect gene
regulation, we screened different databases, in order to detect
miRNA candidates that inhibit collagen I and IV synthesis in HSC
upon HGF stimulation. In the 39UTR sequences of the collagen-1
and collagen-4 mRNA, potential binding sites for the members of
the let-7 family were detected. A number of other miRNA species
that might affect collagen type-I and -IV synthesis, such as miR-
106a/b, miR-20a/b, miR-26a/b, miR-374a/b, miR-186 were
also identified by in silico analyses (summarized in Table 1).
Strikingly, all of the collagen-1 and -4 transcripts contained
binding sites for members of the miRNA-29 family in their 39UTR
(Table 1). Since miR-29 is thought to be involved in modulating
expression of extracellular matrix components (Table S3)
[30,31,32,34], this makes them promising candidates for collagen
I and IV repression after HGF stimulation of HSC.
Table 1. miRNAs with putative binding sites in transcripts of collagen 1 and 4.
Putative Targets col1A1 col1A2 col4A1 col4A2 col4A3 col4A4 col4A5 col4A6
miRNAs with putative
bindings sites in
collagen 1 and 4 mRNA
hsa-let-7a +++ +
hsa-let-7b +++ +
hsa-let-7c +++ +
hsa-let-7d +++ +
hsa-let-7e +++ +
hsa-let-7f +++ +
hsa-let-7g +++ +
hsa-let-7i +++ +
hsa-miR-106a +++ +
hsa-miR-106b +++ +
hsa-miR-125a-5p ++ ++
hsa-miR-1297 ++++
hsa-miR-17 +++ +
hsa-miR-202 ++ ++
hsa-miR-20a +++ +
hsa-miR-20b +++ +
hsa-miR-26a ++++
hsa-miR-26b ++++
hsa-miR-326 ++ ++
hsa-miR-374a +++ +
hsa-miR-374b +++ +
hsa-miR-410 + +++
hsa-miR-544 ++ ++
hsa-miR-93 +++ +
hsa-miR-98 +++ +
more than 4 putative binding sites in the 39UTR of col1 and col4 subunits
hsa-miR-23a +++ ++
hsa-miR-23b +++ ++
hsa-miR-381 +++ + +
hsa-miR-495 + +++ +
hsa-miR-300 +++ + +
hsa-miR-590-3p ++ +++
hsa-miR-186 +++++ ++
putative binding sites in the 39UTR of all col1 and col4 subunits
hsa-miR-29a ++++++++
hsa-miR-29b ++++++++
hsa-miR-29c ++++++++
doi:10.1371/journal.pone.0024568.t001
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myofibroblastic HSC. Interestingly, the expression of mature miR-
29a, but not of miR-29b, was contrary to the collagen expression
during myofibroblastic transition. Thus, whereas col1A2 and
col4A1 collagen expression was highly increased in myofibroblas-
tic HSC, the levels of miR-29a were suppressed (Figure 3 A, B).
Analysis of the transcriptional levels of the primary precursor
miRNA (pri-miRNA) revealed that pri-miR-29b/c transcript
levels are only moderately suppressed, but that the miR-29a/b
gene of chromosome 7 undergoes predominant transcriptional
repression upon myofibroblastic transition of HSC.
In order to study miR-29 function in collagen synthesis, we
inserted the 39-UTR sequences downstream of a luciferase
reporter (Figure 4 A). During progression of liver fibrosis, collagen
IV is most prominently upregulated among ECM components [6].
Therefore, in addition to collagen-1, the collagen-4 mRNA could
be an important target of miR-29 in HSC after HGF stimulation.
Indeed, insertion of the 39-UTR of col4A1 and col4A5
downstream of the luciferase reporter gene lead to a reduction
in luciferase expression after treatment of HSC with ago-miR-29a,
mimicking miR-29a (Figure 4).
Among the putative miR-29 binding sites of the collagen
mRNA (shown in the Table S4), the following sites were chosen for
our further analyses, due to the suggestions of Bartel et al. [50] to
function most likely as an inhibitory miR-29 interaction sequence:
the region of positon 29–35 in the col4A1 39-UTR, of postion
404–410 in the col4A5, positon 903–909 in the col1A1, and of
position 506–512 in the col1A2 39-UTR (Table S4). To
demonstrate the specificity of miR-29 for the binding sites, in
the 39-UTRs two point mutations were incorporated to abolish the
putative miR-29 recognition sequences of the collagen-4 mRNA
(col4A1, col4A5) and collagen-1 transcripts (col1A1 and col1A2).
Co-transfection of HSC-T6 with the reporter plasmids and ago-
miR-29a reduced reporter activity of the wild type controls, but
not of the mutated collagen type I and IV constructs (Figure 5 A–
D).
Furthermore, transfection of ago-miR-29a and ago-miR-29b
into HSC suppressed transcription and protein synthesis of
collagen type I and IV ((Figure 6A, B). Together, these data
demonstrated that miR-29 specifically inhibits transcription and
protein expression of collagen I and IV. In order to analyze if
other features of myofibroblastic transition were affected by miR-
29, we determined SMA expression in miR-29 treated HSC,
because increased SMA assembly is one of the most important
features of myofibroblastic transition (Figure S1 A). However,
overexpression of miR-29 in myofibroblastic HSC did not affect
the expression of SMA (Figure S1 D).
miR-29a and miR-29b are downregulated during
experimental liver fibrosis in rat
Next, we induced experimental fibrosis by bile duct occlusion
(BDO) in rats and studied the miRNA-29 expression during liver
fibrogenesis. After four weeks of BDO both hepatic inflammation
and collagen accumulation was evident in histological sections
(Figure 7 A). Hydroxyproline determination indicates significant
enhancement of matrix deposition in BDO treated livers (Figure 7
B). Thus, BDO induced severe liver fibrosis, when compared to
livers of sham-operated animals. Consistent with the antifibrogenic
and inhibitory function of miR-29 in collagen I and IV synthesis
and the increase of col1A2 and col4A2 (Figure 7 B), we observed a
significant reduction in hepatic miR-29a and miR-29b levels in
this experimental BDO model (Figure 7 C). This loss of the miR-
29a and miR-29b in fibrotic BDO treated livers is attended by
reduced levels of HGF upon fibrosis (Figure 7 D).
Figure 3. Reciprocal expression of the collagen subunits, col1A1 and col4A2, and primary and mature miR-29. RNA of primary HSC in
the quiescent stage (day 3 of primary culture) and after myofibroblastic activation (day 7 of primary culture) was analyzed for mRNA col1A2 and
col4A1 levels (A), as wells as for the levels of mature miR-29a and miR-29b (B), and the primary transcripts of the miR-29a/b and miR-29b/c gene (C).
doi:10.1371/journal.pone.0024568.g003
Figure 4. miR-29 interaction with the 39-UTR of col4A1 and col4A5 transcripts. The 39-UTR of col4A1 (1382 bp) or col4A5 (786 bp) mRNA
was subcloned downstream of the Renilla luciferase reporter (hRluc) of the psiCHECK
TM-2 vector (A). Reporter plasmids were cotransfected into HSC-
T6 in combination with scrambled miRNA or miR-29a mimic (ago-miR-29a), respectively, and luciferase reporter expression was determined by the
hRluc luminescence measurement normalized to firefly luminescence (hluc+) (B–C).
doi:10.1371/journal.pone.0024568.g004
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promoted by HGF
Stimulation of primary HSC and myofibroblastic HSC-T6 cells
with TGF-b decreased significantly the expression of miR-29a and
miR-29b in vitro (Figure 8). In contrast, the incubation of primary
and transdifferentiated HSC with the recombinant hHGF elicited
a marked upregulation of the miR-29a/b levels (Figure 8). To
address the question if the antagonistic influence of TGF-b and
HGF can be also observed in other species or fibroblastic cells of
other organs, we stimulated primary skin fibroblasts with both
TGF-b and HGF. In agreement with the data on rat HSC, miR-
29 is repressed by TGF-b, but upregulated by HGF (Figure S2).
Figure 5. Interaction of miR-29a with the binding regions of col1A1, col1A2, col4A1 and col4A5 39-UTR transcripts. Putative miR-29
binding sites in the collagen col1A1 (A), col1A2 (B), col4A1 (C) and col4A5 (D) 39-UTR (wt) and the corresponding mutated sequences (mu) carrying
two point mutations (bold and underlined) were cloned into psiCHECK
TM-2 vector. The reporter plasmids were co-transfected into HSC-T6 cells with
either scrambled miRNA or miR-29a mimic (ago-miR-29a), respectively. Insertion of the miR-29 binding sites (wt), but not with mutated binding site
(mu), resulted in reduced reporter gene expression by miR-29a treated HSC (A–D).
doi:10.1371/journal.pone.0024568.g005
Antifibrotic Action of HGF by miR-29 Induction
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24568Figure 6. Repression of collagen synthesis by miR-29a and miR-29b. mRNA quantification of collagen subunits in HSC treated either with
miR-29a, miR-29b (ago-miR-29a, ago-miR-29b), or scrambled miRNA by Real-Time PCR (A). The col1A1, col1A2, col4A1, and col4A5 mRNA levels were
normalized to HPRT expression. Furthermore, collagen I and IV protein levels (col I, col IV) were determined by immunoblotting and subsequent
densitometric quantification (B).
doi:10.1371/journal.pone.0024568.g006
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24568Therefore, miR-29 expression appears to be reciprocally
regulated by profibrogenic (TGF-b) and antifibrogenic growth
factors (HGF) in HSC, suggesting that miR-29 occupies a central
role in responding to the antagonistic actions of HGF and TGF-b
in regulating collagen synthesis in activated and transdifferentiated
HSC.
Overexpression of miR-29 can overcome TGF-b mediated
induction of col1A1
After demonstrating that repression of the collagen-inhibiting
miR-29 is an important downstream TGF–b effect, we studied if
miR-29 overexpression can overcome the profibrogenic features
mediated by TGF-b such as col1A1 induction. For this purpose,
HSC-T6 cells were transfected with miR-29a mimics (ago-
miR29a) in comparison to scrambled or miR-29-silencing miRNA
(antago-miR-29). Transfection of HSC with miR-29a mimics lead
to a 10-fold overexpression of miR-29a. In HSC that express low
levels of miR-29a due to transfection with scrambled miRNA or
with a miR-29a silencer, TGF-b treatment highly induced col1A1
synthesis. However, col1A1 induction by TGF-b was only
marginal in HSC, that highly overexpress miR-29a after
transfection with miR-29a mimics (Figure 9). Thus, miR-29a is
able to lower significantly the profibrogenic features of TGF-b in
collagen induction.
Discussion
In the present study we investigated the effects of the opposing
action of TGF-b and HGF on miR-29 regulated collagen synthesis
by HSC during liver fibrosis. After transdifferentiation into
myofibroblasts, HSC constitute the main matrix producing cell
type of the fibrotic liver [1,4]. Our findings demonstrate that
myofibroblastic transdifferentiation is accompanied by the loss of
HGF synthesis on the one hand, and a tremendous increase of Met
receptor expression on the other hand (Figure 1). Previous data
have shown that the transition of HSC into myofibroblasts is
triggered by paracrine but also by autocrine TGF-b stimulation
[12,51]. Accordingly, TGF-b treatment of HSC leads to decreased
HGF expression [29], but enhanced Met receptor synthesis
(Figure 1). Although Ikeda et al have suggested that Met receptor
Figure 7. Reduced miR-29a and miR-29b expression in livers after BDO. Liver tissues from bile duct obstructed (BDO) rats showed hepatic
inflammation and fibrosis shown by haematoxylin-eosin (HE), van Gieson, and Gomori staining (A). HE histology clearly shows the loss of liver
architecture and inflammation after BDO. van Gieson and Gomori stainings revealed the enhancement of connective tissue and the formation of
septa (arrows indicate matrix deposition stained in red by van Gieson or in dark brown by Gomori, respectively). Hydroxyproline levels in livers of
sham operated (N=5) and of BDO rats (N=5) were determined and col1A2 and col4A2 mRNA levels were quantified by Real Time PCR (B).
Additionally, miR-29a and miR-29b levels (C) and HGF and c-met transcripts (D) were quantified by Real-Time PCR. While miR-29 and HGF expression
was significantly reduced (C,D), hydroxyproline and collagen mRNA were signifcantly increased in BDO livers (B) (*: p,0.05 **:p,0.01; ***: p,0.001).
doi:10.1371/journal.pone.0024568.g007
Figure 8. Contrary effects of HGF and TGF-b on miR-29 expression in HSC. miR-29a expression in HSC after 3 days (3d) of primary culture (A)
and miR-29a and miR-29b expression in myofibroblastic HSC-T6 (B). HSC were not stimulated (2) or treated (+) with either TGF-b or hHGF and miR-
29a/b levels were determined by Real Time-PCR analysis.
doi:10.1371/journal.pone.0024568.g008
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response to TGF-b and its association with the pro-fibrotic effects
of TGF-b has not been previously shown. TGF-b is the main
fibrotic mediator that I) induces the synthesis of ECM components
such as collagen type-I and -IV and other collagens [19] II)
influences the balance of matrix metalloproteinase (MMP)
secretion and their inhibitors [52], and III) affects a wide range
of growth factor expression profiles in HSC [1,4]. The opposed
effect of TGF-b on HGF expression and its receptor Met
demonstrates that the changing role of HSC in the paracrine
HGF stimulation - from a HGF-releasing cell type to a HGF-
influenced cell type - is embedded in the regenerative and fibrotic
alterations upon chronic liver disease.
Thus, HSC take center stage during fibrosis in responding to the
opposing effects of TGF-b and HGF on collagen synthesis. In
renal fibroblasts, Yang et al. showed that converse signaling of
HGF and TGF-b is due to competition for ERK1/2 mediated
inhibition of smad2/3 phoshorylation [48]. Upon TGF-b
stimulation of HSC smad2/3 act as the main signal transducers
initiating ECM synthesis and myofibroblastic a-smooth-muscle
actin expression [12,51], whereas HGF attenuates TGF-b induced
Smad-2/3 nuclear translocation and accumulation [48]. However,
blocking of the smad pathway by RNA interference displays that
not only the Erk1/2 inhibitory effect on the smad2/3 pathway, but
also the HGF mediated activation of Akt pathway is involved in
repressing the profibrogenic signalling TGF- b by HGF [49].
In the present study, we now collect evidence that in response to
the counteracting HGF / TGF-b signals the miR-29 levels in HSC
are contrarily regulated. Recent reports have shown that altered
miRNA levels are associated with the phenotypical changes of
HSC during the myofibroblastic transition process including the
induction of ECM proteins [53,54]. Our in silico target analyses
identified various miRNA species putatively suppressing collagen
synthesis. In this respect, the members of the miR-29 family are
the most promising candidates because they are repressed during
myofibroblastic transition and they hold highly conserved binding
sites in the 39-UTR of the various subunits of collagen 1 and 4
(Table 1). Indeed, our in vitro data reveal a definite inhibition of
collagen type IV, that is the most upregulated collagen form in the
fibrotic liver [6], by miR-29. These findings are in agreement with
the data of Du et al. [33] and recent reports showing the miR-29
regulation of elastin, fibullin and collagen I synthesis [30,31,
32,34,35].
Keeping with the antifibrotic function of miR-29, miR-29 is
reduced in liver biopsies after liver intoxication in mice and after
chronic liver disease in humans [35]. The reduced levels of miR-
29 during fibrosis are associated with an increase of extracellular
miR-29 in serum depending on the fibrotic stage (manuscript in
preparation). Furthermore, our in vitro and in vivo studies on HSC
or on BDO-treated fibrotic livers, respectively, suggest that the loss
of miR-29 in HSC after TGF-b exposure and during liver
fibrogenesis leads to the abolishment of collagen type I and IV
repression. Conversely, upregulation of miR-29 levels was
observed after stimulation of HSC with the antifibrotic mediator
HGF (Figure 8), previously shown to inhibit expression of various
collagens [21,48,49]. Interestingly, our findings proved that
upregulation of miR-29a efficiently can overcome the profibro-
genic influence of TGF-b on collagen synthesis (Figure 9). Thus,
our findings convincingly demonstrate that HGF mediates
antifibrotic signals by influencing miR-29 expression and thereby
counteracting the profibrotic activity of TGF-b.
Supporting Information
Figure S1 a-SMA expression in HSC. During myofibro-
blastic transition of primary HSC in culture (A) and in the HSC-
T6 cells after HGF (B) and TGF-b treatment (C). SMA expression
was shown by immunochemistry using the monoclonal FITC-
labeled 1A4 SMA antibody (Sigma Aldrich) (A) or by real-time
PCR (B-D). Transfection of HSC-T6 with ago-miR-29a or ago-
miR-29b did not result in altered SMA expression when compared
to scrambled miRNA treated HSC-T6 cells.
(TIF)
Figure S2 miR-29 expression in human skin fibroblasts
after stimulation with HGF. Human primary skin fibroblasts,
isolated and cultured according to Zhang et al. (J. Cell Sci, 119 (Pt
9): 1886–1895), were not stimulated (/) or treated for 24 h with
40 ng hHGF or 10 ng TGF-b as described in ‘‘Material and
Methods’’ for the stimulation procedure of HSC-T6 cells. miR-
29a levels were determined by Real Time-PCR analysis.
(TIF)
Figure 9. Diminished effect of TGF-b on col1A1 expression in miR-29 treated HSC. The myofibroblastic HSC-T6 cells were transfected with
scrambled miRNA, miR-29 mimic (ago-miR-29), or with a miR-29 silencer (antago-miR-29). TGF-b treatment resulted in highly increased col1A1
expression in HSC cells treated with scrambled miRNA or with antago-miR-29, but only a moderate col1A1 induction in miR-29 overexpressing HSC
after transfection with ago-miR-29.
doi:10.1371/journal.pone.0024568.g009
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